Ronald Anderson Selected Research

Streptococcus pneumoniae plY protein

1/2020	Pneumococcal virulence factors in community-acquired pneumonia.
4/2018	Multifaceted Role of Pneumolysin in the Pathogenesis of Myocardial Injury in Community-Acquired Pneumonia.
1/2017	Pneumolysin as a potential therapeutic target in severe pneumococcal disease.
12/2016	The Role of Streptococcus pneumoniae in Community-Acquired Pneumonia.
1/2016	Prevalence, pathogenesis, therapy, and prevention of cardiovascular events in patients with community-acquired pneumonia.
2/2013	Effects of cigarette smoke condensate on pneumococcal biofilm formation and pneumolysin.
5/2005	Pneumolysin as a vaccine and drug target in the prevention and treatment of invasive pneumococcal disease.
8/2003	Pneumolysin in the immunopathogenesis and treatment of pneumococcal disease.
6/2002	The role of pneumolysin in the pathogenesis of Streptococcus pneumoniae infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ronald Anderson Research Topics

Disease

21	Neoplasms (Cancer) 05/2022 - 01/2008
18	Infections 01/2022 - 05/2005
17	Inflammation (Inflammations) 01/2022 - 08/2003
15	Pneumonia (Pneumonitis) 01/2021 - 10/2006
15	Pneumococcal Infections 01/2020 - 06/2002
10	Rheumatoid Arthritis 01/2019 - 01/2010
6	HIV Infections (HIV Infection) 01/2021 - 01/2011
4	Tuberculosis (Tuberculoses) 01/2022 - 02/2013
4	Neutropenia 03/2021 - 11/2020
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 08/2015
4	Chronic Obstructive Pulmonary Disease (COPD) 01/2019 - 12/2010
3	Sepsis (Septicemia) 06/2022 - 01/2019
3	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 01/2020 - 02/2012
3	Asthma (Bronchial Asthma) 01/2013 - 05/2005
2	Septic Shock (Toxic Shock Syndrome) 06/2022 - 01/2020
2	Critical Illness (Critically Ill) 06/2022 - 01/2020
2	Shock 06/2022 - 01/2020
2	Hypoaldosteronism (Hyporeninemic Hypoaldosteronism) 06/2022 - 01/2020
2	Hematologic Neoplasms (Hematological Malignancy) 03/2021 - 12/2018
2	Enterocolitis 12/2020 - 01/2018
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2020 - 01/2019
2	Acquired Immunodeficiency Syndrome (AIDS) 01/2020 - 01/2017
2	Cardiotoxicity 01/2020 - 01/2018
2	Pulmonary Tuberculosis 01/2019 - 06/2017
2	Leukemia 12/2018 - 04/2010
2	Genetic Predisposition to Disease (Genetic Predisposition) 06/2018 - 01/2013
2	Pneumococcal Pneumonia 01/2011 - 04/2009
2	Hodgkin Disease (Hodgkin's Disease) 03/2010 - 03/2010
2	Chronic Granulomatous Disease 11/2004 - 06/2004
1	Hemorrhagic Shock 06/2022
1	Hyperaldosteronism (Conn Syndrome) 06/2022
1	Triple Negative Breast Neoplasms 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Cardiac Arrhythmias (Arrythmia) 01/2022
1	Thrombophilia 01/2022
1	Xeroderma Pigmentosum (Kaposi's Disease) 01/2022
1	Superinfection 04/2021
1	Coinfection 04/2021
1	Febrile Neutropenia 03/2021

Drug/Important Bio-Agent (IBA)

12	CytokinesIBA 01/2022 - 04/2007
12	Anti-Bacterial Agents (Antibiotics)IBA 04/2021 - 05/2005
11	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2013
9	Streptococcus pneumoniae plY proteinIBA 01/2020 - 06/2002
8	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2018
7	Virulence Factors (Pathogenicity Factors)IBA 01/2020 - 08/2003
6	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2022 - 08/2003
6	MacrolidesIBA 01/2020 - 08/2003
5	ChemokinesIBA 01/2022 - 06/2016
5	Pharmaceutical PreparationsIBA 01/2022 - 05/2005
5	Acute-Phase Proteins (Acute-Phase Protein)IBA 06/2017 - 01/2010
4	Clofazimine (Lamprene)FDA Link 01/2022 - 02/2012
4	VaccinesIBA 01/2020 - 06/2002
4	Conjugate VaccinesIBA 01/2020 - 08/2003
4	Anti-Citrullinated Protein AntibodiesIBA 06/2018 - 06/2010
3	Chemokine CCL5IBA 01/2022 - 01/2018
3	NivolumabIBA 01/2021 - 01/2019
3	SmokeIBA 01/2019 - 01/2011
3	Rheumatoid FactorIBA 06/2018 - 06/2010
3	AutoantibodiesIBA 06/2018 - 01/2010
3	Anti-Infective Agents (Microbicides)IBA 03/2015 - 10/2006
2	MineralocorticoidsIBA 06/2022 - 01/2020
2	ReninIBA 06/2022 - 01/2020
2	GlucocorticoidsIBA 06/2022 - 01/2020
2	FludrocortisoneIBA 06/2022 - 01/2020
2	Angiotensin IIIBA 06/2022 - 01/2020
2	Immune Checkpoint ProteinsIBA 05/2022 - 01/2022
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022 - 01/2021
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 03/2021 - 11/2020
2	AntigensIBA 01/2021 - 01/2011
2	pembrolizumabIBA 01/2021 - 01/2019
2	AntibodiesIBA 12/2020 - 06/2018
2	Proteins (Proteins, Gene)FDA Link 10/2020 - 03/2009
2	Antirheumatic Agents (DMARD)IBA 01/2019 - 05/2015
2	Peptides (Polypeptides)IBA 06/2018 - 08/2003
2	NADPH Oxidases (NAD(P)H oxidase)IBA 11/2004 - 06/2004
1	Hydrocortisone (Cortisol)FDA LinkGeneric 06/2022
1	AldosteroneIBA 06/2022
1	Phenobarbital (Luminal)FDA Link 05/2022
1	Estrogen ReceptorsIBA 05/2022
1	Progesterone Receptors (Progesterone Receptor)IBA 05/2022
1	Rifampin (Rifampicin)FDA LinkGeneric 01/2022
1	fibroblast growth factor 21IBA 01/2022
1	Oxygen (Dioxygen)IBA 01/2022
1	Macrophage Colony-Stimulating FactorIBA 01/2022
1	Pyrazinamide FDA LinkGeneric 01/2022
1	Isoniazid (Ftivazide)FDA LinkGeneric 01/2022
1	Vitamin D FDA LinkGeneric 01/2022
1	Growth Differentiation Factor 15IBA 01/2022
1	Chemokine CX3CL1IBA 01/2022
1	Ethambutol (Myambutol)FDA LinkGeneric 01/2022
1	ElectrolytesIBA 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	Biosimilar PharmaceuticalsIBA 03/2021
1	Zidovudine (Retrovir)FDA LinkGeneric 01/2021

Therapy/Procedure

29	Therapeutics 01/2021 - 05/2005
9	Drug Therapy (Chemotherapy) 11/2020 - 05/2005
8	Immunotherapy 03/2021 - 01/2018
6	Highly Active Antiretroviral Therapy (HAART) 01/2020 - 01/2014
2	Radiotherapy 01/2021 - 02/2019
2	Critical Care (Surgical Intensive Care) 03/2016 - 08/2015